TE-1 Xenograft Model Service for Esophageal Squamous Cell Carcinoma (ESCC)

TE-1 Xenograft Model Service for Esophageal Squamous Cell Carcinoma (ESCC) provides a validated preclinical platform for evaluating novel therapeutic strategies against one of the most aggressive upper gastrointestinal malignancies. Alfa Cytology delivers comprehensive TE-1 xenograft model services encompassing tumor establishment, longitudinal monitoring, and endpoint analysis, enabling researchers to advance their ESCC drug development programs with confidence and reproducibility.

Overview of TE-1 Xenograft Model for Esophageal Squamous Cell Carcinoma (ESCC)

The TE-1 xenograft model is established by implanting TE-1 human esophageal squamous cell carcinoma cells into immunodeficient mice, creating a subcutaneous tumor that recapitulates the histological and molecular features of the original patient tumor. TE-1 cells, derived from a well-differentiated ESCC, exhibit epithelial morphology with desmosomes and interdigitated microvilli, and demonstrate abundant mitochondria and rough endoplasmic reticulum under electron microscopy. When transplanted into immunodeficient hosts, these cells form tumors that closely resemble the histological architecture of the primary esophageal squamous cell carcinoma, making this model a reliable tool for investigating tumor biology, growth factor signaling, and therapeutic resistance in ESCC.

This model has been extensively utilized in preclinical research to explore molecular mechanisms of squamous cell carcinoma, including studies on epidermal growth factor (EGF) receptor expression and downstream signaling pathways. TE-1 cells demonstrate a reduced number of high-affinity EGF receptors compared to normal esophageal epithelial cells, with markedly altered responses to EGF stimulation, providing a valuable system for understanding growth factor dysregulation in ESCC progression. The TE-1 xenograft model supports a wide range of applications, including drug efficacy screening, biomarker discovery, combination therapy evaluation, and mechanistic studies of therapeutic resistance in esophageal squamous cell carcinoma.

Figure 1. In vitro characterisation of the TE-1 cell lines edited for mCAIX expression. (Kalnina Z, et al., 2025)

Cell Line Information: TE-1

The TE-1 cell line was established from a well-differentiated squamous cell carcinoma of the esophagus obtained from a 58-year-old Asian male patient. TE-1 cells exhibit epithelial morphology and grow as both isolated and piled-up colonies in adherent culture. Cytogenetic analysis reveals a male karyotype with distinctive marker chromosomes. The cell line demonstrates differentiation-associated structures including desmosomes and interdigitated microvilli visible under scanning electron microscopy, along with abundant organelles including mitochondria and rough endoplasmic reticulum observed via transmission electron microscopy.

Our Services

Alfa Cytology offers end-to-end TE-1 xenograft model services tailored to your preclinical research objectives, from tumor establishment and longitudinal monitoring to comprehensive endpoint analysis including tumor volume measurement, histopathological evaluation, and biomarker assessment. Our experienced team ensures rigorous quality control, standardized protocols, and timely data delivery to accelerate your ESCC therapeutic development pipeline.

Workflow of TE-1 Xenograft Model Construction

The construction of the TE-1 xenograft model follows a standardized protocol optimized for consistent tumor formation and reliable preclinical outcomes. The process involves cell preparation, immunodeficient mouse selection, subcutaneous implantation, tumor monitoring, and endpoint analysis, with each step executed under strict quality control measures to ensure reproducibility and data integrity.

1. Step 1: Cell Harvesting and Preparation --- TE-1 cells are maintained in adherent culture and harvested during the logarithmic growth phase at 80-90% confluence to ensure optimal viability and tumorigenic potential. Cells are washed with PBS, trypsinized, and resuspended in serum-free medium or PBS at a concentration of 1-5 x 10^7 cells/mL, with viability confirmed by trypan blue exclusion.
2. Step 2: Cell-Matrigel Mixture Preparation --- The cell suspension is mixed with Matrigel at a 1:1 ratio on ice to obtain a final concentration of 1-5 x 10^7 cells/mL, providing a supportive extracellular matrix that enhances engraftment efficiency and tumor formation. The mixture is kept cold to prevent premature gelling and maintain cell viability.
3. Step 3: Animal Preparation and Subcutaneous Injection --- Immunodeficient mice (e.g., BALB/c nude mice or NOD/SCID mice) aged 4-6 weeks are acclimatized under specific pathogen-free conditions. The dorsal skin at the injection site (posterior axilla or inguinal region) is disinfected with 75% ethanol, and 100-200 microL of the cell-Matrigel suspension is injected subcutaneously using a 27G needle.
4. Step 4: Tumor Monitoring and Measurement --- Tumor formation is monitored daily, with palpable nodules typically appearing within 7-14 days. Tumor dimensions are measured twice weekly using calipers, and volume is calculated using the formula: Tumor Volume = (Length x Width^2) / 2. Tumor burden is maintained within ethical limits, not exceeding 10% of body weight or 15 mm in any dimension.
5. Step 5: Endpoint Analysis and Sample Collection --- At the predetermined endpoint or when humane limits are reached, mice are humanely euthanized and tumor masses are excised, weighed, and processed for downstream analyses including histopathology (H&E staining), immunohistochemistry, biomarker profiling, and genomic characterization.

Figure 2: Schematic workflow illustrating the derivation and construction of the TE-1 Xenograft Model at Alfa Cytology.

Case Study-TE-1 Xenograft Model Development

In a representative TE-1 xenograft model development project, immunodeficient mice were inoculated subcutaneously with TE-1 cells mixed with Matrigel, resulting in successful tumor engraftment with consistent growth kinetics across the cohort. Tumors reached measurable volumes within 10-14 days post-inoculation and demonstrated steady exponential growth over the study duration. Histopathological examination confirmed well-differentiated squamous cell carcinoma morphology with keratin pearl formation and intercellular bridges, consistent with the original patient tumor characteristics. Endpoint analysis revealed robust tumor take rates and provided high-quality tissue samples for downstream biomarker and pharmacodynamic assessments, validating the model's utility for preclinical drug evaluation in esophageal squamous cell carcinoma research.

Why Choose Alfa Cytology?

Alfa Cytology stands out as a trusted partner for TE-1 xenograft model services, combining scientific expertise, rigorous quality standards, and client-focused project management to deliver reliable preclinical data for your ESCC research programs.

• Validated TE-1 xenograft models with proven tumor take rates and consistent growth kinetics across multiple studies.
• Comprehensive service portfolio covering tumor establishment, longitudinal monitoring, and multi-parameter endpoint analysis.
• Strict adherence to animal welfare guidelines with humane endpoint monitoring and regulatory compliance.
• Experienced scientific team with deep expertise in esophageal cancer biology and xenograft model development.
• Customizable study designs to accommodate specific research objectives, including combination therapy and biomarker evaluation.
• Timely data delivery with detailed study reports and high-quality histopathological and molecular analysis outputs.
• Competitive pricing and flexible project timelines to support both academic and pharmaceutical research programs.

Contact Us

Ready to advance your esophageal squamous cell carcinoma research with our TE-1 xenograft model services? Please reach out to us today via our inquiry form or email to learn more about our TE-1 Xenograft Model services.

For research use only. Not intended for any clinical use.